List of Excipients in Branded Drug CHILDRENS LORATADINE ORAL

« Back to Dashboard

Generic Drugs Containing CHILDRENS LORATADINE ORAL

Company	Ingredient	NDC	Excipient
Major Pharmaceuticals	loratadine	0904-6767	EDETATE DISODIUM
Major Pharmaceuticals	loratadine	0904-6767	GLYCERIN
Major Pharmaceuticals	loratadine	0904-6767	MALTITOL

What are the Most Frequently-Used Excipients in CHILDRENS LORATADINE ORAL?

# Of NDCs	Excipient
1	AQUA
5	EDETATE DISODIUM
5	GLYCERIN

Children’s Loratadine Oral Excipient Strategy and Commercial Opportunities

Last updated: October 27, 2026

Children’s loratadine oral products are mature, low-cost antihistamine formulations with limited active-ingredient exclusivity and substantial competition from store brands. Commercial differentiation depends primarily on palatability, preservative strategy, dosing accuracy, sugar reduction, packaging, manufacturing efficiency, and channel positioning rather than new loratadine chemistry.

The core product is usually loratadine oral solution or syrup at 5 mg per 5 mL, administered once daily to children aged 2 years and older under U.S. labeling. The principal commercial opportunity is a differentiated, regulatorily compliant liquid formulation that improves taste, minimizes excipient concerns, reduces packaging and shipping costs, or supports premium pediatric positioning.

What is the regulatory status of children’s loratadine oral?

Children’s loratadine oral products are generally marketed in the United States under the FDA’s over-the-counter antihistamine framework or through abbreviated regulatory pathways for products equivalent to an approved reference product.

Attribute	Commercial position
Active ingredient	Loratadine
Common pediatric strength	5 mg/5 mL
Dosage form	Oral solution or syrup
Typical pediatric use	Temporary relief of allergy symptoms and hives
Usual age positioning	Children 2 years and older, subject to product labeling
Administration	Once daily
Regulatory category	OTC monograph or approved equivalent product, depending on product and market
Prescription status	Loratadine is generally nonprescription in the United States
Primary competitors	Cetirizine, levocetirizine, fexofenadine, diphenhydramine and branded or store-brand loratadine

The FDA’s OTC Monograph M012 covers antihistamine active ingredients and permitted uses, doses, labeling and conditions for nonprescription marketing. Loratadine is also listed in FDA-approved drug products and in the Orange Book for approved prescription and abbreviated applications, although many current children’s products are sold as OTC products rather than as conventional prescription medicines.[1,2]

The formulation must comply with applicable requirements for active ingredient concentration, labeling, dosing instructions, child-resistant packaging where required, stability, microbial quality, and inactive ingredients. The product must not create an unreasonable risk of accidental overdose, particularly because children’s liquid medicines are frequently administered by caregivers using household utensils.

What excipients are used in children’s loratadine oral formulations?

The excipient system normally contains a vehicle, sweetener, flavor, buffering agent, preservative or preservative system, viscosity modifier and solubilization aid. The exact composition varies by manufacturer.

Typical excipient classes

Excipient function	Common formulation options	Commercial purpose	Key risk
Vehicle	Purified water	Primary liquid carrier	Microbial contamination and stability
Sweetener	Sucrose, sorbitol, sucralose, sodium saccharin	Taste masking	Sugar load, laxation or aftertaste
Flavor	Fruit flavors such as grape, berry or cherry	Improves acceptance	Flavor mismatch and allergen concerns
Buffer	Citric acid, sodium citrate, phosphate systems	Controls pH	Taste, compatibility and preservative performance
Preservative	Sodium benzoate, potassium sorbate, parabens	Controls microbial growth	Regulatory, taste and consumer-perception issues
Humectant	Glycerin, propylene glycol	Mouthfeel and solubilization	Sensory profile and pediatric acceptability
Thickener	Cellulose derivatives, xanthan gum or similar polymers	Reduces settling and improves dosing feel	Pourability, viscosity and manufacturing complexity
Chelator	Disodium edetate	Supports preservative and stability performance	Excipient burden and labeling review
Solubilizer	Polysorbate or polyethylene glycol systems	Supports loratadine dispersion or solubilization	Oxidative impurities and compatibility

Loratadine has poor water solubility. A successful liquid formulation therefore requires either a cosolvent and solubilization system or a controlled suspension approach. A clear oral solution may offer strong visual appeal and dose uniformity, but it can require higher levels of solubilizers, pH control and taste masking. A suspension can reduce solubilization demands but introduces settling, redispersibility and dose-uniformity risks.

What excipient strategy is strongest for a new pediatric loratadine product?

The strongest strategy is a low-sugar, pleasant-tasting, preservative-controlled oral liquid with robust dose uniformity and a simple label. The product should be designed around the intended commercial claim rather than around excipient novelty alone.

Strategy 1: Sugar-free oral solution

A sugar-free formulation can use sorbitol, sucralose, sodium saccharin or combinations of high-intensity sweeteners. Glycerin can improve mouthfeel, while a fruit flavor system can mask loratadine’s bitterness.

Advantages include:

• Positioning for parents limiting sugar intake.
• Easier alignment with diabetes-conscious household purchasing.
• Reduced risk of dental-health objections associated with sucrose-containing syrups.
• Compatibility with premium and pharmacy-store-brand marketing.

The main technical risks are aftertaste, cooling effects from polyols, gastrointestinal tolerance at higher doses and inadequate masking of loratadine bitterness. Excess sorbitol can create a laxative warning or poor pediatric tolerability. High-intensity sweeteners can leave metallic or lingering notes.

Strategy 2: Preservative-reduced or preservative-free suspension

A preservative-free product can target caregivers seeking fewer excipients. This approach is more difficult for a multidose bottle because repeated opening creates microbial risk.

A preservative-free design may require:

• Unit-dose packaging.
• A sterile or controlled manufacturing process.
• A low-water-activity system.
• Specialized dispensing technology.
• Shorter in-use storage periods.
• Stronger package-integrity controls.

The commercial premium may not offset packaging and manufacturing costs unless the product is aimed at a specific channel, such as hospital discharge, specialty pediatric care or premium direct-to-consumer sales.

Strategy 3: High-palatability fruit formulation

Taste remains the most practical source of differentiation. Loratadine’s bitterness can be addressed through layered taste masking:

1. pH optimization.
2. Sweetener blending.
3. Flavor selection.
4. Viscosity adjustment.
5. Use of bitterness blockers or ion-exchange approaches where technically justified.

A single flavor is unlikely to suit all pediatric age groups. Grape and berry flavors often have broad OTC recognition, while natural citrus or mixed-fruit systems can support a cleaner-label position. Flavor selection must be tested in the final matrix because pH, preservatives, polyols and surfactants can alter flavor perception.

Strategy 4: Clear solution with dosing-device differentiation

A clear solution gives caregivers visual confirmation that the product is homogeneous and free of visible particles. This can support a premium presentation. The product should be paired with an oral syringe or calibrated dosing cup rather than relying on a household spoon.

The commercial advantage is strongest when the dosing device is integrated into the packaging and the label communicates dose volume clearly. The formulation itself is not enough. The entire dose-delivery system must minimize measurement errors.

What formulation patents protect children’s loratadine oral products?

Most commercial protection for a children’s loratadine liquid is unlikely to come from broad patents covering loratadine itself. Loratadine was disclosed and developed decades ago, and basic composition-of-matter exclusivity is no longer commercially relevant for new generic or OTC entrants.

Potentially protectable subject matter includes:

Patentable area	Potential claim scope	Commercial value
Taste masking	Specific excipient ratios, flavor systems or bitterness blockers	Moderate if supported by reproducible sensory data
Solubilization	pH, cosolvent, surfactant or complexation system	Moderate
Suspension stability	Particle-size distribution, suspending polymer and redispersibility	Moderate
Preservative system	Specific preservative combination and pH window	Low to moderate
Packaging	Dosing closure, unit-dose container or child-resistant system	Moderate
Device integration	Bottle-and-syringe systems or dose-metering closures	Moderate
Stability	Reduced degradation or improved color and flavor retention	Moderate
Manufacturing process	Mixing, particle engineering or filling conditions	Low to moderate unless difficult to design around
Combination products	Loratadine with another active ingredient	Potentially higher, but regulatory and safety complexity rises

A formulation patent should claim a defined technical result, such as improved loratadine concentration stability, reduced precipitation, improved redispersibility or demonstrated bitterness reduction. Claims directed only to generic excipient categories are vulnerable to invalidity or design-around arguments.

Trade-secret protection may be more effective than patenting for flavor ratios, processing order, mixing energy, impurity controls and sensory-screening methods. The strongest portfolio combines a narrow formulation patent, confidential manufacturing parameters and packaging protection.

When does loratadine lose exclusivity?

Loratadine’s original active-ingredient exclusivity has expired. The commercial market is therefore open to generic and private-label competition, subject to applicable OTC monograph, ANDA, NDA or local regulatory requirements.

Exclusivity type	Current commercial relevance
Loratadine composition of matter	Expired
Original branded product exclusivity	Expired
Pediatric liquid formulation exclusivity	Generally not a barrier to entry
OTC monograph access	Available if the product meets monograph conditions
Formulation-specific patents	Must be assessed product by product
Trademark protection	May remain for brand names, but does not block generic entry
Data exclusivity	Generally not a meaningful barrier for a mature active ingredient

No single expiration date should be treated as the market entry date for all children’s loratadine liquids. Product-specific patents, approved labeling, manufacturing certifications, trademarks and state-level requirements can affect launch timing. For mature OTC loratadine, however, the principal entry barriers are execution and distribution rather than basic exclusivity.

What is the Orange Book status of children’s loratadine oral?

The Orange Book is relevant to approved prescription and abbreviated applications, but it does not function as a complete patent register for every OTC monograph product. A company evaluating a children’s loratadine oral launch must distinguish among:

• A monograph-compliant OTC product.
• An OTC product marketed under an approved NDA.
• An ANDA referencing an approved loratadine product.
• A private-label product supplied by a contract manufacturer.
• A product marketed outside the United States.

Orange Book patent listings, if any, should be reviewed at the specific reference-product and application level. An absence of an Orange Book-listed patent does not establish that no contractual, trademark, packaging or formulation rights exist. It does indicate that the standard Hatch-Waxman patent-listing pathway may not capture the full competitive landscape.[2]

Are Paragraph IV challenges relevant to children’s loratadine oral?

Paragraph IV litigation is less central for a conventional children’s loratadine OTC launch than for a prescription product with active Orange Book patents. A Paragraph IV certification becomes relevant when an ANDA applicant references a listed drug with unexpired patents and asserts that the patents are invalid, unenforceable or not infringed.

For a mature loratadine liquid:

• Broad loratadine patent barriers are generally absent.
• Product-specific liquid formulation patents may create a narrower risk.
• A monograph pathway may avoid some ANDA patent dynamics.
• Private-label and OTC competition can enter without a conventional Paragraph IV campaign if the regulatory route does not require reference to a patented product.
• Litigation risk is more likely to involve formulation, labeling, trademark, packaging or manufacturing rights than the active ingredient.

A company should not assume that a low Paragraph IV risk means zero legal exposure. Patent owners can pursue infringement claims based on formulation or device patents even when the active ingredient is unprotected.

What manufacturing and IP barriers affect loratadine oral liquids?

The most significant technical barrier is maintaining consistent loratadine content in a liquid system with acceptable taste and stability.

Key manufacturing risks

• Incomplete dissolution or nonuniform suspension.
• Precipitation during storage or temperature cycling.
• Preservative loss or inadequate antimicrobial effectiveness.
• Flavor degradation.
• Color change.
• Foaming during mixing.
• Viscosity drift.
• Inconsistent fill volume.
• Dose nonuniformity after storage.
• Interaction between bottle, closure and formulation.

A solution product should undergo accelerated and long-term stability testing, preservative-effectiveness testing where applicable, extractables and leachables assessment, microbial limits testing, assay and impurity analysis, and in-use stability evaluation. A suspension requires additional redispersibility and dose-uniformity work.

Manufacturing scale-up can change particle wetting, shear exposure, air incorporation and order-of-addition effects. These factors can undermine a formulation that performs well at laboratory scale.

Which companies are challenging the children’s loratadine market?

The competitive field includes branded manufacturers, large generic companies, pharmacy chains, mass retailers and contract manufacturers. The leading commercial reference is Claritin, while store brands commonly use labels such as loratadine oral solution or children’s allergy relief.

Competitor type	Typical advantage	Threat to a new entrant
Original branded loratadine suppliers	Brand recognition and shelf placement	High in retail visibility
National generic manufacturers	Scale and pharmacy distribution	High on price
Retail private labels	Low customer-acquisition cost and retailer access	High in value channels
Contract manufacturers	Flexible supply and turnkey compliance	Moderate
Pediatric-focused brands	Taste and caregiver trust	Moderate
Competing antihistamines	Therapeutic substitution	High

Cetirizine and fexofenadine are important substitutes. Diphenhydramine remains relevant despite sedation concerns because of its low price and broad consumer familiarity. A new loratadine liquid must compete against the whole pediatric allergy category, not only against other loratadine products.

How does children’s loratadine compare with competing oral antihistamines?

Product	Common pediatric liquid positioning	Dosing frequency	Differentiation issue
Loratadine	Non-drowsy allergy relief	Once daily	Mature and heavily commoditized
Cetirizine	Allergy relief with strong consumer recognition	Once daily	May be perceived as more effective by some caregivers
Fexofenadine	Non-drowsy allergy relief	Once or twice daily, depending on product	Higher cost and flavor positioning
Diphenhydramine	Allergy and cold-related relief	More frequent dosing	Sedation and safety concerns
Levocetirizine	Non-drowsy allergy relief	Once daily	Smaller but established market

Loratadine’s once-daily schedule is a commercial advantage. It is offset by low prices, extensive availability and limited opportunity to claim clinical superiority without new supporting evidence.

What commercial opportunities exist for children’s loratadine oral?

The highest-probability opportunities are formulation and channel improvements rather than new therapeutic claims.

Attractive opportunity areas

1. Sugar-free, low-aftertaste formulation
   Suitable for pharmacy, grocery and online channels.

2. Premium dosing system
   Include a calibrated oral syringe, tamper-evident closure and clear age-based instructions.

3. Private-label platform
   Develop one validated formulation that can support multiple retailer brands and bottle sizes.

4. Concentrated liquid
   A lower-volume dose can reduce shipping and improve portability, but it requires careful overdose prevention and strong labeling.

5. Unit-dose sachets or cups
   Useful for travel, schools and institutional settings, although packaging cost is higher.

6. Allergen-conscious excipient profile
   Avoid unnecessary dyes, reduce excipient complexity and communicate the formulation clearly.

7. Sustainability positioning
   Use recyclable packaging and lower-volume bottles without compromising child resistance or stability.

8. Global adaptation
   Develop a formulation platform adaptable to different sweeteners, preservatives, labeling rules and approved pediatric concentrations.

Revenue exposure is most sensitive to retail price, retailer placement, supply reliability and product reviews. A formulation premium is difficult to sustain unless the product produces a visible consumer benefit, such as improved taste, easier dosing or fewer undesirable excipients.

What generic launch scenarios exist?

Launch scenario	Product profile	Margin outlook	Principal risk
Value generic	Standard 5 mg/5 mL syrup or solution	Low	Price competition
Store brand	Retailer-exclusive product	Low to moderate	Dependence on retailer
Premium sugar-free	Improved taste and excipient profile	Moderate	Consumers may not pay premium
Device-led product	Integrated syringe or metered closure	Moderate	Packaging cost and complexity
Unit-dose product	Portable, preservative-reduced presentation	Moderate to high	Higher manufacturing cost
Global platform	Country-specific versions	Moderate	Regulatory fragmentation

The fastest route is usually a standard monograph-compliant product using a qualified contract manufacturer. The strongest long-term defensibility comes from a formulation platform with documented sensory, stability and dosing advantages.

How strong is the patent estate for children’s loratadine oral?

The estate is weak at the active-ingredient level and potentially moderate at the formulation and packaging levels.

IP category	Estimated strategic strength
Loratadine molecule	Very low
Basic oral solution	Low
Specific taste-masking system	Moderate
Preservative-free multidose system	Moderate if technically validated
Dosing device	Moderate
Manufacturing process	Low to moderate
Brand and trade dress	Moderate
Trade secrets	Moderate
Regulatory exclusivity	Low for mature generic products

A defensible launch should avoid dependence on a single formulation patent. The better structure is a layered package covering the composition, process controls, packaging configuration, brand assets and confidential sensory know-how.

Key Takeaways

• Children’s loratadine oral is a mature, highly competitive OTC category.
• The active ingredient provides little meaningful exclusivity protection.
• The main commercial opportunity is differentiated formulation design.
• Sugar-free, pleasant-tasting, low-excipient and dosing-device-led products have the clearest positioning options.
• Clear solutions require careful solubilization and taste masking because loratadine has poor water solubility.
• Suspensions can reduce solubilization pressure but create settling and dose-uniformity risks.
• Preservative-free multidose products are technically difficult and may not deliver sufficient commercial return.
• Orange Book and Paragraph IV analysis must be performed at the specific product and regulatory-application level.
• Formulation patents can provide moderate protection, but trade secrets and packaging rights may be equally important.
• Retail access, supply reliability and consumer acceptance will usually determine commercial performance more than patent scope.

FAQs

Can children’s loratadine oral be marketed without a patent?

Yes. Loratadine is a mature active ingredient, and a compliant OTC or approved generic product can generally enter without owning a new active-ingredient patent. Product-specific formulation, packaging and trademark rights still require review.

Is a sugar-free loratadine liquid commercially differentiated?

It can be, but sugar-free status alone may not support a durable premium. The strongest product combines sugar reduction with good taste, low aftertaste, accurate dosing and a simple excipient profile.

Is loratadine oral solution better than loratadine suspension?

A solution can provide a cleaner appearance and eliminate settling, but it may require more complex solubilization and taste masking. A suspension can simplify active-ingredient dispersion but requires robust redispersibility and dose-uniformity controls.

Does a children’s loratadine product need an oral syringe?

An oral syringe is not universally required for every presentation, but it is commercially and safety advantageous. It improves dose measurement compared with household spoons and supports premium pediatric positioning.

Can a new loratadine formulation obtain patent protection?

Yes, if it contains a novel and non-obvious composition, process, packaging system or technical effect. Broad claims covering loratadine with ordinary sweeteners or preservatives are likely to face significant validity and design-around challenges.

References

1. U.S. Food and Drug Administration. (2023). Antihistamine drug products for over-the-counter human use: Final monograph, 21 C.F.R. Part 341. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (2017). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Food and Drug Administration. (2024). Drug products marketed in the United States that contain loratadine. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.